CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
|
3 Months Ended |
Mar. 31, 2022 |
Mar. 31, 2021 |
| Financial Designation, Predecessor and Successor [Fixed List] |
Successor
|
Predecessor
|
| OPERATING REVENUE: |
|
|
| TOTAL OPERATING REVENUE |
$ 273,544,334
|
$ 151,297,940
|
| OPERATING EXPENSES: |
|
|
| Medical Expenses |
265,820,802
|
146,624,505
|
| Premium Deficiency Reserve |
(1,324,513)
|
2,000,000
|
| Corporate, General and Administrative Expenses |
38,599,412
|
15,059,076
|
| Sales and Marketing Expenses |
864,530
|
270,241
|
| Amortization of Intangibles |
21,161,282
|
|
| Depreciation |
590,549
|
332,548
|
| TOTAL OPERATING EXPENSES |
325,712,062
|
164,286,370
|
| OPERATING LOSS |
(52,167,728)
|
(12,988,430)
|
| OTHER INCOME (EXPENSES): |
|
|
| Interest Expense, net |
(2,761,250)
|
(2,124,286)
|
| Mark-to-Market of Stock Warrants |
(5,861,276)
|
(9,537,996)
|
| TOTAL OTHER INCOME (EXPENSE) |
(8,622,526)
|
(11,662,282)
|
| LOSS BEFORE INCOME TAXES |
(60,790,254)
|
(24,650,712)
|
| PROVISION FOR INCOME TAXES |
0
|
0
|
| NET LOSS |
(60,790,254)
|
(24,650,712)
|
| LESS NET LOSS ATTRIBUTABLE TO REDEEMABLE NON-CONTROLLING INTERESTS |
(50,212,750)
|
|
| NET LOSS ATTRIBUTABLE TO CONTROLLING INTERESTS |
$ (10,577,504)
|
$ (24,650,712)
|
| NET LOSS PER SHARE (BASIC) |
$ (0.25)
|
|
| NET LOSS PER SHARE (DILUTED) |
$ (0.25)
|
|
| Capitated Revenue |
|
|
| OPERATING REVENUE: |
|
|
| TOTAL OPERATING REVENUE |
$ 269,684,815
|
$ 148,964,190
|
| Other Patient Service Revenue |
|
|
| OPERATING REVENUE: |
|
|
| TOTAL OPERATING REVENUE |
$ 3,859,519
|
$ 2,333,750
|